Complement Factor H-Antibody–Associated Hemolytic Uremic Syndrome: Pathogenesis, Clinical Presentation, and Treatment

Abstract

The presence of circulating autoantibodies, primarily to complement factor H antibodies (CFH-Abs) in plasma characterizes the autoimmune form of atypical hemolytic uremic syndrome (aHUS). This acquired form of aHUS defines a distinct subgroup of aHUS patients, which requires diagnostic and treatment approaches in part different from those of the genetically defined forms. The mechanisms leading to CFH-Ab production and disease onset are not completely understood, but CFH-Ab HUS seems to be secondary to a combination of genetic predisposition and environmental factors. Early diagnosis of this specific aHUS entity is important, as prompt induction of plasma exchange and concomitant immunosuppression leads to a favorable outcome. Nevertheless, information on clinical features and outcome in children is limited. Here, we review the literature on the biological and clinical features of CFH-Ab HUS and discuss therapeutic options.

Keywords

complement factor H - complement factor H antibodies - atypical hemolytic uremic syndrome - complement-related diseases - transplantation

• References

• 1 Würzner R, Riedl M, Rosales A, Orth-Höller D. Treatment of enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Semin Thromb Hemost 2014; 40 (4) 508-516
• 2 Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA , et al; French Society of Pediatric Nephrology. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007; 18 (8) 2392-2400
• 3 Zimmerhackl LB, Scheiring J, Prüfer F, Taylor CM, Loirat C. Renal transplantation in HUS patients with disorders of complement regulation. Pediatr Nephrol 2007; 22 (1) 10-16
• 4 Constantinescu AR, Bitzan M, Weiss LS , et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis 2004; 43 (6) 976-982
• 5 Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8 (11) 622-633
• 6 Riedl M, Fakhouri F, Le Quintrec M , et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 2014; 40 (4) 444-464
• 7 Caprioli J, Bettinaglio P, Zipfel PF , et al; Italian Registry of Familial and Recurrent HUS/TTP. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001; 12 (2) 297-307
• 8 Caprioli J, Castelletti F, Bucchioni S , et al; International Registry of Recurrent and Familial HUS/TTP. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003; 12 (24) 3385-3395
• 9 Dragon-Durey MA, Frémeaux-Bacchi V, Loirat C , et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004; 15 (3) 787-795
• 10 Pérez-Caballero D, González-Rubio C, Gallardo ME , et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 2001; 68 (2) 478-484
• 11 Richards A, Buddles MR, Donne RL , et al. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet 2001; 68 (2) 485-490
• 12 Warwicker P, Goodship THJ, Donne RL , et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53 (4) 836-844
• 13 Fremeaux-Bacchi V, Moulton EA, Kavanagh D , et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006; 17 (7) 2017-2025
• 14 Noris M, Brioschi S, Caprioli J , et al; International Registry of Recurrent and Familial HUS/TTP. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003; 362 (9395) 1542-1547
• 15 Richards A, Kemp EJ, Liszewski MK , et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003; 100 (22) 12966-12971
• 16 Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J , et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004; 41 (6) e84
• 17 Kavanagh D, Kemp EJ, Mayland E , et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16 (7) 2150-2155
• 18 Kavanagh D, Richards A, Noris M , et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 2008; 45 (1) 95-105
• 19 Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J , et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007; 104 (1) 240-245
• 20 Frémeaux-Bacchi V, Miller EC, Liszewski MK , et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008; 112 (13) 4948-4952
• 21 Delvaeye M, Noris M, De Vriese A , et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361 (4) 345-357
• 22 Dragon-Durey MA, Loirat C, Cloarec S , et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16 (2) 555-563
• 23 Józsi M, Licht C, Strobel S , et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008; 111 (3) 1512-1514
• 24 Kavanagh D, Pappworth IY, Anderson H , et al. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?. Clin J Am Soc Nephrol 2012; 7 (3) 417-426
• 25 Józsi M, Strobel S, Dahse HM , et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007; 110 (5) 1516-1518
• 26 Abarrategui-Garrido C, Martínez-Barricarte R, López-Trascasa M, de Córdoba SR, Sánchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009; 114 (19) 4261-4271
• 27 Moore I, Strain L, Pappworth I , et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010; 115 (2) 379-387
• 28 Lee BH, Kwak SH, Shin JI , et al. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency. Pediatr Res 2009; 66 (3) 336-340
• 29 Strobel S, Hoyer PF, Mache CJ , et al. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 2010; 25 (1) 136-144
• 30 Dragon-Durey MA, Blanc C, Marliot F , et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009; 46 (7) 447-450
• 31 Hofer J, Janecke AR, Zimmerhackl LB , et al; German-Austrian HUS Study Group. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013; 8 (3) 407-415
• 32 Kwon T, Dragon-Durey MA, Macher MA , et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2008; 23 (6) 2088-2090
• 33 Le Quintrec M, Zuber J, Noel LH , et al. Anti-Factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am J Transplant 2009; 9 (5) 1223-1229
• 34 Dragon-Durey MA, Sethi SK, Bagga A , et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010; 21 (12) 2180-2187
• 35 Sinha A, Gulati A, Saini S , et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 2013; ; doi:10.1038/ki.2013.373
• 36 Boyer O, Balzamo E, Charbit M , et al. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am J Kidney Dis 2010; 55 (5) 923-927
• 37 Sana G, Dragon-Durey MA, Charbit M , et al. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol 2014; 29 (1) 75-83
• 38 Reusz GS, Szabó AJ, Réti M , et al. Diagnosis and classification of hemolytic uremic syndrome: the Hungarian experience. Transplant Proc 2011; 43 (4) 1247-1249
• 39 Noone D, Waters A, Pluthero FG , et al. Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol 2014; 29 (5) 841-851
• 40 Skerka C, Zipfel PF, Müller D , et al. The autoimmune disease DEAP-hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36 (6) 625-632
• 41 Waters AM, Pappworth I, Marchbank K , et al. Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T. Am J Transplant 2010; 10 (1) 168-172
• 42 Kim JJ, McCulloch M, Marks SD, Waters A, Noone D. The clinical spectrum of hemolytic uremic syndrome secondary to complement factor H autoantibodies (epub ahead of print). Clin Nephrol 2013;
• 43 Uslu-Gökceoğlu A, Doğan CS, Comak E, Koyun M, Akman S. Atypical hemolytic uremic syndrome due to factor H autoantibody. Turk J Pediatr 2013; 55 (1) 86-89
• 44 Jodele S, Licht C, Goebel J , et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013; 122 (12) 2003-2007
• 45 Ricklin D, Cines DB. TMA: beware of complements. Blood 2013; 122 (12) 1997-1999
• 46 Goodship TH, Pappworth IY, Toth T , et al. Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol Immunol 2012; 52 (3-4) 200-206
• 47 Sethi S, Sukov WR, Zhang Y , et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis 2010; 56 (5) 977-982
• 48 Nozal P, Strobel S, Ibernon M , et al. Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease. Clin Kidney J 2012; 5: 133-136
• 49 Foltyn Zadura A, Zipfel PF, Bokarewa MI , et al. Factor H autoantibodies and deletion of complement factor H-related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. Arthritis Res Ther 2012; 14 (4) R185
• 50 Dhillon B, Wright AF, Tufail A , et al. Complement factor h autoantibodies and age-related macular degeneration. Invest Ophthalmol Vis Sci 2010; 51 (11) 5858-5863
• 51 Dragon-Durey MA, Blanc C, Roumenina LT , et al. Anti-factor H autoantibodies assay. Methods Mol Biol 2014; 1100: 249-256
• 52 Blanc C, Roumenina LT, Ashraf Y , et al. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J Immunol 2012; 189 (7) 3528-3537
• 53 Strobel S, Abarrategui-Garrido C, Fariza-Requejo E, Seeberger H, Sánchez-Corral P, Józsi M. Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome. Kidney Int 2011; 80 (4) 397-404
• 54 Hageman GS, Hancox LS, Taiber AJ , et al; AMD Clinical Study Group. Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann Med 2006; 38 (8) 592-604
• 55 Holmes LV, Strain L, Staniforth SJ , et al. Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32. PLoS ONE 2013; 8 (4) e60352
• 56 Kraiczy P, Würzner R. Complement escape of human pathogenic bacteria by acquisition of complement regulators. Mol Immunol 2006; 43 (1-2) 31-44
• 57 Kopp A, Strobel S, Tortajada A , et al. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3. J Immunol 2012; 189 (4) 1858-1867
• 58 Noris M, Caprioli J, Bresin E , et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5 (10) 1844-1859
• 59 Geerdink LM, Westra D, van Wijk JA , et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 2012; 27 (8) 1283-1291
• 60 Malina M, Gulati A, Bagga A, Majid MA, Simkova E, Schaefer F. Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics 2013; 131 (1) e331-e335
• 61 Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36 (6) 673-681
• 62 de Jorge EG, Macor P, Paixão-Cavalcante D , et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 2011; 22 (1) 137-145
• 63 Dubois EA, Cohen AF. Eculizumab. Br J Clin Pharmacol 2009; 68 (3) 318-319
• 64 Legendre CM, Licht C, Muus P , et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368 (23) 2169-2181
• 65 Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Frémeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011; 7 (1) 23-35
• 66 Campistol JM, Arias M, Ariceta G , et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2013; 33 (1) 27-45
• 67 Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V ; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8 (11) 643-657
• 68 Ardissino G, Tel F, Testa S , et al. Skin involvement in atypical hemolytic uremic syndrome. Am J Kidney Dis 2014; 63 (4) 652-655
• 69 Hebecker M, Alba-Domínguez M, Roumenina LT , et al. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J Immunol 2013; 191 (2) 912-921
• 70 Zuber J, Le Quintrec M, Morris H, Frémeaux-Bacchi V, Loirat C, Legendre C. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando) 2013; 27 (4) 117-125
• 71 Zipfel PF, Mache C, Müller D, Licht C, Wigger M, Skerka C ; European DEAP-HUS Study Group. DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatr Nephrol 2010; 25 (10) 2009-2019